These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25016399)

  • 1. Role of aldosterone blockade in resistant hypertension.
    Egan BM; Li J
    Semin Nephrol; 2014 May; 34(3):273-84. PubMed ID: 25016399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Resistant Hypertension.
    Egan BM
    Ethn Dis; 2015 Nov; 25(4):495-8. PubMed ID: 26674466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N; Kalaitzidis R; Bakris GL
    Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study.
    Brambilla G; Bombelli M; Seravalle G; Cifkova R; Laurent S; Narkiewicz K; Facchetti R; Redon J; Mancia G; Grassi G
    J Hypertens; 2013 Oct; 31(10):2018-24. PubMed ID: 23838657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum potassium levels predict blood pressure response to aldosterone antagonists in resistant hypertension.
    Shlomai G; Sella T; Sharabi Y; Leibowitz A; Grossman E
    Hypertens Res; 2014 Dec; 37(12):1037-41. PubMed ID: 24671013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists.
    Glicklich D; Frishman WH
    Drugs; 2015 Apr; 75(5):473-85. PubMed ID: 25787734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension.
    Sharabi Y; Adler E; Shamis A; Nussinovitch N; Markovitz A; Grossman E
    Am J Hypertens; 2006 Jul; 19(7):750-5. PubMed ID: 16814132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
    Bakris G; Yang YF; Pitt B
    Hypertension; 2020 Jul; 76(1):144-149. PubMed ID: 32520623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension.
    Dudenbostel T; Calhoun DA
    Am J Hypertens; 2017 Feb; 30(2):103-109. PubMed ID: 27609503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension.
    Jansen PM; Frenkel WJ; van den Born BJ; de Bruijne EL; Deinum J; Kerstens MN; Arnoldus JH; Woittiez AJ; Wijbenga JA; Zietse R; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Feb; 31(2):404-13. PubMed ID: 23249826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension.
    Colussi G; Catena C; Sechi LA
    J Hypertens; 2013 Jan; 31(1):3-15. PubMed ID: 23011526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress in the diagnosis and treatment of primary aldosteronism.
    Yoshida Y; Shibata H
    Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone Antagonists or Renin-Guided Therapy for Treatment-Resistant Hypertension: A Comparative Effectiveness Pilot Study in Primary Care.
    Egan BM; Laken MA; Sutherland SE; Qanungo S; Fleming DO; Cook AG; Hester WH; Jones KW; Jebaily GC; Valainis GT; Way CF; Wright MB; Davis RA
    Am J Hypertens; 2016 Aug; 29(8):976-83. PubMed ID: 27076600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A; Mahgoub M; Hall M; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status.
    Ghazi L; Dudenbostel T; Lin CP; Oparil S; Calhoun DA
    J Hypertens; 2016 May; 34(5):1005-10. PubMed ID: 26886564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Evidence Supporting the Use of Mineralocorticoid Receptor Blockers in Drug-Resistant Hypertension.
    Narayan H; Webb DJ
    Curr Hypertens Rep; 2016 Apr; 18(5):34. PubMed ID: 27072827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of spironolactone on blood pressure in subjects with resistant hypertension.
    Chapman N; Dobson J; Wilson S; Dahlöf B; Sever PS; Wedel H; Poulter NR;
    Hypertension; 2007 Apr; 49(4):839-45. PubMed ID: 17309946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.